GlassScriptPhysician profile
Nader A Dakak
NPI 1457332652
$20,548.46
in general payments reported to CMS, 2019-2025
39 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,675 · 2020: $830 · 2021: $1,024 · 2022: $1,638 · 2023: $10K · 2024: $876 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,743 · Food and Beverage: $3,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,742.79 |
| Food and Beverage | $3,639.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,574.82 | 2022-2025 | Resolute Onyx, Hawkone, Symplicity G3 |
| Abbott Laboratories | $2,433.76 | 2019-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit, Confirm Rx |
| Medtronic Vascular, INC. | $2,427.45 | 2019 | |
| Pfizer INC. | $577.00 | 2019-2025 | |
| Amgen INC. | $543.80 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $536.08 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $505.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $485.42 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $342.01 | 2022-2024 | Watchman, Watchdog, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $340.61 | 2019-2025 | Eliquis, Camzyos |
| Shockwave Medical, INC | $316.34 | 2019-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $314.43 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $215.39 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $207.20 | 2019-2025 | Amvuttra |
| Abiomed | $182.78 | 2022-2024 | Impella |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $174.37 | 2021-2025 | Ozempic, Wegovy |
| Amarin Pharma, INC. | $144.50 | 2019-2022 | |
| Cardiovascular Systems INC. | $133.02 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.52 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $110.91 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.85 | 2019-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $99.42 | 2022-2023 | Arcalyst |
| Cook Medical LLC | $72.92 | 2019-2024 | Cook |
| Atricure, INC. | $71.98 | 2022-2024 | |
| Arbor Pharmaceuticals, INC. | $71.73 | 2019-2020 | |
| Terumo Medical Corporation | $64.70 | 2023 | Angio-Seal |
| Lexicon Pharmaceuticals, INC. | $59.50 | 2023 | Inpefa |
| W. L. Gore & Associates, INC. | $49.35 | 2019-2024 | Gore Viabahn Endoprosthesis With Heparin |
| Corcept Therapeutics | $48.22 | 2024-2025 | Korlym |
| Kiniksa Pharmaceuticals International, Plc | $42.98 | 2024 | Arcalyst |
| Cordis US Corp. | $30.20 | 2023 | Outback Elite |
| Inspire Medical Systems, INC. | $24.97 | 2024 | Inspire |
| Cardiva Medical, INC. | $23.73 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Heartflow, INC. | $22.27 | 2025 | |
| Amryt Pharma Holdings LTD | $19.62 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.13 | 2019 | |
| Silk Road Medical, INC. | $17.59 | 2019 | |
| Chiesi USA, INC. | $17.06 | 2025 | Kengreal |
| Vivaquant INC, Dba Rhythm Express | $10.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Dakak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.